KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Accounts Payables: 2009-2025

Historic Accounts Payables for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $798.4 million.

  • Biomarin Pharmaceutical's Accounts Payables rose 11.57% to $798.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $798.4 million, marking a year-over-year increase of 11.57%. This contributed to the annual value of $607.0 million for FY2024, which is 11.15% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Accounts Payables of $798.4 million as of Q3 2025, which was up 16.69% from $684.2 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Accounts Payables' 5-year high stood at $798.4 million during Q3 2025, with a 5-year trough of $399.2 million in Q1 2021.
  • Over the past 3 years, Biomarin Pharmaceutical's median Accounts Payables value was $628.2 million (recorded in 2025), while the average stood at $649.8 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first dropped by 12.16% in 2021, then soared by 40.29% in 2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Accounts Payables (Quarterly) stood at $498.3 million in 2021, then grew by 14.99% to $573.0 million in 2022, then climbed by 19.23% to $683.1 million in 2023, then dropped by 11.15% to $607.0 million in 2024, then climbed by 11.57% to $798.4 million in 2025.
  • Its Accounts Payables stands at $798.4 million for Q3 2025, versus $684.2 million for Q2 2025 and $628.2 million for Q1 2025.